1. Mannkind's inhalers won 1st and 3rd place with Merck coming in second in global international competition.
2. The new inhaler needed actual trials in human not just bioequivalance testing thus the delay.
Sure the FDA could say now after saying they want Mannkind to test in 4 year olds when the company only wanted to test in 12 year olds, but is that likely?
What are the side affect of the drug? a slight cough in a few that goes away? They compaired this inhaled drugs lung function against an injected insulin and found no significant difference. So basically breathing air against Afrezza.
No daily titration
No carbohydrate counting
No sight scaring
12 minutes to peaking
3 hours totally out of the body
No hyperglycemic events if used alone in all cases even when you eat nothing!
Superior Glycemic controls
Ha, you beat me to it.
Mannkind has been fairly resilient.
I expect them to remain so. I haven't seen anything to indicate that they have given up
The Fool is wrong and I am tired of them sounding like a broken record.
"Aside from that, aren't these risks common to all biotechs with product in development and therefore kind of a given for this stock?" .........ummmm no. quality biotech management doesnt dilute their shareholders to the point of irrelevancy and have to go beg its feeble incoherent founder for repeated life lines after tgeyve spent everything on S Class leases, wine, perpetual catering and sporting events.